CETP inhibition with Anacetrapib Decreases Fractional Clearance Rates of HDL Apolipoprotein A-I and Plasma CETP

OBJECTIVE: Anacetrapib, an inhibitor of cholesteryl ester transfer protein (CETP) activity, increases plasma concentrations of HDL-C, apoA-I, apoA-II, and CETP. The mechanisms responsible for these treatment-related increases in apolipoproteins and plasma CETP are unknown. We performed a randomized,...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Arterioscler Thromb Vasc Biol
Asıl Yazarlar: Reyes-Soffer, Gissette, Millar, John S., Ngai, Colleen, Jumes, Patricia, Coromilas, Ellie, Asztalos, Bela, Johnson-Levonas, Amy O., Wagner, John A., Donovan, Daniel S., Karmally, Wahida, Ramakrishnan, Rajasekhar, Holleran, Stephen, Thomas, Tiffany, Dunbar, Richard L., deGoma, Emil M., Rafeek, Hashmi, Baer, Amanda L., Liu, Yang, Lassman, Michael E., Gutstein, David E., Rader, Daniel J., Ginsberg, Henry N.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2016
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4911016/
https://ncbi.nlm.nih.gov/pubmed/26966279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/ATVBAHA.115.306680
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller